Akebia Therapeutics (AKBA) Net Margin (2017 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Net Margin of 16.91% for Q1 2026, down 2757.0% year-over-year from 0.64% in Q1 2025, and up 20.42% quarter-over-quarter from 21.25% in Q4 2025.
Akebia Therapeutics (AKBA) Net Margin (2017 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Net Margin for 10 consecutive years, with 16.91% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 2757.0% year-over-year to 16.91%; the TTM figure through Mar 2026 stood at 8.83% (up 1568.0% YoY), while the FY2025 annual figure was 2.26%, up 4107.0% from the prior year.
- Net Margin rose to 16.91% in Q1 2026 per AKBA's latest filing, from 21.25% in the prior quarter.
- Across five years, Net Margin topped out at 23.3% in Q2 2022 and bottomed at 83564.47% in Q1 2022.
- Historically, Net Margin has averaged 4940.21% across 5 years, with a median of 19.82% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin sank 8343516 bps — and 2023, when it jumped 8349729 bps.
- Akebia Therapeutics' Net Margin stood at 7.39% in 2022, then jumped by 115 bps to 1.09% in 2023, then plunged by 4589 bps to 49.04% in 2024, then surged by 57 bps to 21.25% in 2025, then rose by 20 bps to 16.91% in 2026.
- Business Quant data shows AKBA's Net Margin at 16.91% in Q1 2026, 21.25% in Q4 2025, and 0.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -13.91% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 9.28% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.51% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -3.16% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.06% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.95% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | -18.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.13% |
| Mar 31, 2026 | -16.91% |
| Dec 31, 2025 | -21.25% |
| Sep 30, 2025 | 0.92% |
| Jun 30, 2025 | 0.40% |
| Mar 31, 2025 | 10.66% |
| Dec 31, 2024 | -49.04% |
| Sep 30, 2024 | -53.54% |
| Jun 30, 2024 | -19.66% |
| Mar 31, 2024 | -55.16% |
| Dec 31, 2023 | 1.09% |
| Sep 30, 2023 | -34.46% |
| Jun 30, 2023 | -19.82% |
| Mar 31, 2023 | -67.18% |
| Dec 31, 2022 | -7.39% |
| Sep 30, 2022 | -111.05% |
| Jun 30, 2022 | 23.30% |
| Mar 31, 2022 | -83,564.47% |
| Dec 31, 2021 | 44.81% |
| Sep 30, 2021 | -122.13% |